Trial · NCT00487162
The Association Between Peri-Operative Hyperglycemia and Major Morbidity and Mortality
NCT00487162, Not applicable, Terminated, University of Medicine and Dentistry of New Jersey; results first posted 2014-04-03
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The Association Between Peri-Operative Hyperglycemia and Major Morbidity and Mortality. Trials, record NCT00487162. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00487162
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Association Between Peri-Operative Hyperglycemia and Major Morbidity and Mortality
- NCT number
- NCT00487162
- Status
- Terminated
- Phases
- Not applicable
- Enrollment
- 56 participants, actual
- Lead sponsor
- University of Medicine and Dentistry of New Jersey
- Conditions
- Hyperglycemia
- Interventions
- intensive glycemic control, conventional glycemic control
- First posted
- 2007-06-15
- Last updated
- 2016-11-08
- Results first posted
- 2014-04-03
- Limitations and caveats
- Study was terminated. No final conclusion drawn. A sentinel article was published in Feb 2009 issue of Anesthesiology which questioned the safety of intense insulin therapy/strict glycemic control.
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Wound Infection | 7-10 days post op | |
| Secondary | Hemodynamic Instability | 0-48 hours post op |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Wound Infection | 7-10 days post op | no analysis was done as the study was terminated due to patient safety concerns | ||
| SECONDARY | Hemodynamic Instability | 0-48 hours post op | no analysis was done as the study was terminated due to patient safety concerns |
Source ClinicalTrials.gov
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Conventional Glycemic Control | 30 | |
| Overall Study | STARTED | Intensive Glycemic Control | 26 | |
| Overall Study | COMPLETED | Conventional Glycemic Control | 28 | |
| Overall Study | COMPLETED | Intensive Glycemic Control | 21 | |
| Overall Study | NOT COMPLETED | Conventional Glycemic Control | 2 | |
| Overall Study | NOT COMPLETED | Intensive Glycemic Control | 5 |
Source ClinicalTrials.gov
Adverse events2
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | hypoglycemia | Endocrine disorders | Conventional Glycemic Control | 0 | 28 | |
| other | hypoglycemia | Endocrine disorders | Intensive Glycemic Control | 1 | 21 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Conventional Glycemic Control | ||
| Total, all-cause mortality | Intensive Glycemic Control | ||
| Total, other adverse events | Conventional Glycemic Control | 0 | 28 |
| Total, other adverse events | Intensive Glycemic Control | 1 | 21 |
| Total, serious adverse events | Conventional Glycemic Control | 0 | 28 |
| Total, serious adverse events | Intensive Glycemic Control | 0 | 21 |
Source ClinicalTrials.gov
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Conventional Glycemic Control vs Intensive Glycemic Control: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00487162
GET https://conductscience.org/api/trials/v1/NCT00487162/registered